» Articles » PMID: 35340531

Anti-SARS-CoV-2 Activities of Five-membered Heterocycle-substituted Benzimidazoles

Overview
Journal J Mol Struct
Publisher Elsevier
Specialty Chemistry
Date 2022 Mar 28
PMID 35340531
Authors
Affiliations
Soon will be listed here.
Abstract

The manuscript deals with cost-effective synthesis, structural characterization and SARS-CoV-2 screening activity of 5-membered heterocycle-substituted benzimidazole derivatives, 1-((1H-pyrrol-2-yl)methyl)-2-(1H-pyrrol-2-yl)-1H-benzo[d]imidazole (), 2-(furan-2-yl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole (), 2-(thiophen-2-yl)-1-(thiophen-2-ylmethyl)-1H-benzo[d]imidazole (). The benzimidazole compounds were synthesized through a green-synthetic approach by coupling of 5-membered heterocyclic-carboxaldehyde and o-phenylenediamine in water under an aerobic condition. The compounds were characterized by various spectroscopic methods and X-ray structural analysis. The suitable single-crystals of the methyl derivative of were grown as which crystallized in a monoclinic system and the thiophene groups co-existed in a nearly a perpendicular orientation. Further, anti-SARS-CoV-2 proficiency of the synthetic derivatives is evaluated against main protease (M) and non-structural proteins (nsp2 and nsp7) of SARS-CoV-2. Molecular docking and molecular dynamics analysis of the ligands () against M and nsp2 and nsp7 for 50 ns reveal that turns out to be the superlative antiviral candidate against M, nsp2 and nsp7 of SARS-CoV-2 as evident from the binding score and stability of the ligand-docked complexes with considerable binding energy changes.

Citing Articles

Identification of potential MMP-8 inhibitors through virtual screening of natural product databases.

Wang Y, Chen X In Silico Pharmacol. 2025; 13(1):11.

PMID: 39780770 PMC: 11704116. DOI: 10.1007/s40203-024-00299-w.


In Vitro Screening of an In-House Library of Structurally Distinct Chemotypes Towards the Identification of Novel SARS-CoV-2 Inhibitors.

Tonelli M, Sparatore A, Bassanini I, Francesconi V, Sparatore F, Maina K Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770510 PMC: 11676875. DOI: 10.3390/ph17121668.


AI Promoted Virtual Screening, Structure-Based Hit Optimization, and Synthesis of Novel COVID-19 S-RBD Domain Inhibitors.

Gkekas I, Katsamakas S, Mylonas S, Fotopoulou T, Magoulas G, Tenchiu A J Chem Inf Model. 2024; 64(22):8562-8585.

PMID: 39535926 PMC: 11600510. DOI: 10.1021/acs.jcim.4c01110.


A Comprehensive Update of Anti-COVID-19 Activity of Heterocyclic Compounds.

Nazir M, Ahmad M, Aslam S, Rafiq A, Al-Hussain S, Zaki M Drug Des Devel Ther. 2024; 18:1547-1571.

PMID: 38737333 PMC: 11088867. DOI: 10.2147/DDDT.S450499.


Recent Advances in Nitrogen-Containing Heterocyclic Scaffolds as Antiviral Agents.

Kanupriya , Mittal R, Sharma V, Biswas T, Mishra I Med Chem. 2024; 20(5):487-502.

PMID: 38279757 DOI: 10.2174/0115734064280150231212113012.


References
1.
Mudi P, Mahanty A, Kotakonda M, Prasad S, Bhattacharyya S, Biswas B . A benzimidazole scaffold as a promising inhibitor against SARS-CoV-2. J Biomol Struct Dyn. 2022; 41(5):1798-1810. DOI: 10.1080/07391102.2021.2024448. View

2.
Zhang D, Hamdoun S, Chen R, Yang L, Ip C, Qu Y . Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry. Pharmacol Res. 2021; 172:105820. PMC: 8364251. DOI: 10.1016/j.phrs.2021.105820. View

3.
Ma J, Chen Y, Wu W, Chen Z . Structure and Function of N-Terminal Zinc Finger Domain of SARS-CoV-2 NSP2. Virol Sin. 2021; 36(5):1104-1112. PMC: 8365134. DOI: 10.1007/s12250-021-00431-6. View

4.
Kia R, Fun H, Kargar H . 4-[1-(4-Cyano-benz-yl)-1H-benzimidazol-2-yl]benzonitrile. Acta Crystallogr Sect E Struct Rep Online. 2011; 65(Pt 4):o660-1. PMC: 2969064. DOI: 10.1107/S1600536809006989. View

5.
Pedersen S, Ho Y . SARS-CoV-2: a storm is raging. J Clin Invest. 2020; 130(5):2202-2205. PMC: 7190904. DOI: 10.1172/JCI137647. View